AU4105985A - Implantable formulations of regulatory peptides with controlled release - Google Patents

Implantable formulations of regulatory peptides with controlled release

Info

Publication number
AU4105985A
AU4105985A AU41059/85A AU4105985A AU4105985A AU 4105985 A AU4105985 A AU 4105985A AU 41059/85 A AU41059/85 A AU 41059/85A AU 4105985 A AU4105985 A AU 4105985A AU 4105985 A AU4105985 A AU 4105985A
Authority
AU
Australia
Prior art keywords
controlled release
regulatory peptides
implantable formulations
implantable
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41059/85A
Inventor
Jurgen Kurt Sandow
Heinz-Rudiger Seidel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU4105985A publication Critical patent/AU4105985A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
AU41059/85A 1984-04-11 1985-04-10 Implantable formulations of regulatory peptides with controlled release Abandoned AU4105985A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3413608 1984-04-11
DE19843413608 DE3413608A1 (en) 1984-04-11 1984-04-11 IMPLANTABLE PREPARATIONS OF REGULATORY PEPTIDES WITH CONTROLLED RELEASE AND METHOD FOR THE PRODUCTION THEREOF

Publications (1)

Publication Number Publication Date
AU4105985A true AU4105985A (en) 1985-10-17

Family

ID=6233259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41059/85A Abandoned AU4105985A (en) 1984-04-11 1985-04-10 Implantable formulations of regulatory peptides with controlled release

Country Status (12)

Country Link
EP (1) EP0158277A3 (en)
JP (1) JPS60228411A (en)
KR (1) KR850007559A (en)
AU (1) AU4105985A (en)
DE (1) DE3413608A1 (en)
DK (1) DK162385A (en)
ES (1) ES8607732A1 (en)
GR (1) GR850905B (en)
HU (1) HUT40760A (en)
IL (1) IL74848A0 (en)
PT (1) PT80252B (en)
ZA (1) ZA852639B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587626B2 (en) * 1985-07-29 1989-08-24 Wyeth Holdings Corporation Continuous release peptide composition
AU656897B2 (en) * 1990-07-19 1995-02-23 University Of Kentucky Research Foundation, The Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
US6777386B2 (en) 1996-08-30 2004-08-17 Peptech Limited Sustained peptide-release formulation

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
AU601736B2 (en) * 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
WO1989005138A1 (en) * 1987-12-08 1989-06-15 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
JP2590358B2 (en) * 1988-03-01 1997-03-12 正雄 五十嵐 In utero or vaginal administration preparation for endometriosis treatment
JP2571874B2 (en) * 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド Protein microsphere composition
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
CN103356636A (en) 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein modulators
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
NZ565138A (en) 2005-06-21 2012-02-24 Xoma Technology Ltd IL-1beta Binding antibodies and fragments thereof
DE602007009045D1 (en) * 2006-01-05 2010-10-21 Med Inst Inc TIN-COATED MEDICAL DEVICE
EP2094306A2 (en) 2006-12-20 2009-09-02 XOMA Technology Ltd. Treatment of il-1-beta related diseases
AU2008268461B2 (en) 2007-06-22 2015-04-09 Children's Medical Center Corporation Methods and uses thereof of prosaposin
WO2009067431A2 (en) 2007-11-20 2009-05-28 Cook Incorporated Controlled drug delivery using a zein layer modified with levulinic acid
PL2391650T3 (en) 2007-12-20 2015-03-31 Xoma Us Llc Methods for the treatment of gout
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN101669899B (en) * 2009-09-29 2011-02-02 河北科技大学 Sustained-release implant taking maize protein as main framework material or matrix and use thereof
CA2822026C (en) 2009-12-17 2018-06-12 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
CN101843577A (en) * 2010-04-08 2010-09-29 安徽中医学院 Coating implant using zein as skeleton material and preparation method
CN114010776A (en) 2010-06-09 2022-02-08 疫苗技术股份有限公司 Therapeutic immunization of HIV-infected persons for enhancing antiretroviral therapy
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CN108714212A (en) 2011-05-11 2018-10-30 儿童医疗中心有限公司 More antigens offer immunogenic composition and its method and purposes
US9701731B2 (en) 2011-08-19 2017-07-11 Children's Medical Center Corporation VEGF-binding protein for blockade of angiogenesis
JP6320300B2 (en) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Methods for treating acne
EP4306123A3 (en) 2011-12-22 2024-04-17 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
JP6684490B2 (en) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining regions and uses thereof
JP2015509091A (en) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート Humanized antibody
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
KR102302634B1 (en) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 Modified therapeutic agents and compositions thereof
WO2015057834A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
CN105814083A (en) 2013-10-15 2016-07-27 加州生物医学研究所 Chimeric antigen receptor T cell switches and uses thereof
KR102455171B1 (en) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3529268A1 (en) 2016-10-19 2019-08-28 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
CN115551594A (en) 2019-10-24 2022-12-30 米诺陶治疗公司 Cytokine-modified chimeric antibodies and methods of use thereof
EP4329887A1 (en) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE184774C (en) *
US2895880A (en) * 1955-05-13 1959-07-21 Smith Kline French Lab Sustained release pharmaceutical product
GB935672A (en) * 1960-07-19 1963-09-04 Sterling Drug Inc Sustained release tablet
DE2242844A1 (en) * 1972-08-31 1974-04-11 Wolfgang Joachim Guettner Zein-based aerosol spray - contg carbon dioxide propellant dissolved in solvent (mixt) for zein
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587626B2 (en) * 1985-07-29 1989-08-24 Wyeth Holdings Corporation Continuous release peptide composition
AU656897B2 (en) * 1990-07-19 1995-02-23 University Of Kentucky Research Foundation, The Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
US6777386B2 (en) 1996-08-30 2004-08-17 Peptech Limited Sustained peptide-release formulation
US7309689B2 (en) 1996-08-30 2007-12-18 Peptech Limited Sustained peptide-release formulation

Also Published As

Publication number Publication date
PT80252B (en) 1987-02-03
ES8607732A1 (en) 1986-06-01
PT80252A (en) 1985-05-01
JPS60228411A (en) 1985-11-13
ES542045A0 (en) 1986-06-01
GR850905B (en) 1985-11-25
KR850007559A (en) 1985-12-07
HUT40760A (en) 1987-02-27
DK162385D0 (en) 1985-04-10
DK162385A (en) 1985-10-12
DE3413608A1 (en) 1985-10-24
EP0158277A3 (en) 1987-04-29
EP0158277A2 (en) 1985-10-16
IL74848A0 (en) 1985-07-31
ZA852639B (en) 1985-11-27

Similar Documents

Publication Publication Date Title
AU4105985A (en) Implantable formulations of regulatory peptides with controlled release
AU2189588A (en) Artificial skin
AU4897085A (en) Intracanalicular implant
AU587358B2 (en) Control of retroviruses
AU5295890A (en) Preparation of functional human factor viii
AU1828988A (en) Controlled release formulation
AU4285889A (en) Preparation of catheter
EP0282951A3 (en) Controlled release preparations of active materials
AU8317587A (en) Therapeutic preparations
PH20391A (en) Controlled release pharmaceutical preparations
AU572046B2 (en) The injection of implants into animals
AU5126785A (en) Handling artificial turf
AU6287786A (en) Therapeutic composition
AU588828B2 (en) Controlled release capsule
AU549066B2 (en) Preparation of human insulin
AU613543B2 (en) Preparation of halofluorobenzenes
AU2554884A (en) Subcutaneous implant of estradiol
AU4552389A (en) Preparation of n-acyl-aminomethylphosphonates
AU1823588A (en) Novel compounds and their preparations and formulations
AU4802285A (en) Dental implant
AU3050089A (en) Cosmetic preparation
AU2317088A (en) Pacemaker system
AU578500B2 (en) Preparation of optically active azolylcarbinols
AU6407686A (en) Artificial plant
AU566580B2 (en) Preparation of 1-azidoaldoses